Low-Dose GLP-1 for Maintenance: What Is Known After Goal Weight

Maintenance is the best argument microdosing has, and it still rests on a trial nobody has done. What is well documented is that stopping a GLP-1 is followed by substantial weight regain. What has never been tested is whether a reduced dose holds weight as well as the label dose does. Those are different experiments, and the evidence for the first is routinely presented as evidence for the second.

Why maintenance is a separate question

Losing weight and keeping it off are treated as one problem in most content and as two problems in the trials.

The pivotal weight-loss trials ran 64 to 72 weeks with the dose held at maintenance level throughout. None of them asked what happens if the dose comes down after the loss phase. That question has its own physiology, its own endpoint, and its own trial design, and the field is only starting to run those trials.

What happens when treatment stops

Weight comes back. The STEP 1 extension followed participants after semaglutide was withdrawn and documented substantial regain, with the cardiometabolic improvements achieved during treatment reversing as well.

That finding is why obesity is increasingly treated as a chronic condition requiring ongoing treatment rather than a course of therapy with an end date. It is a strong result and it is not in dispute.

It also reframes what the maintenance question is for. Nobody is asking whether to keep taking something. The evidence has settled that. The open question is what the something should be.

The dose-reduction question has not been trialled

State it plainly: no randomised trial has compared staying on a label maintenance dose against tapering to a reduced dose after goal weight. That is the exact gap microdosing advocacy fills with extrapolation.

The STEP 1 extension compared treatment with no treatment. It says nothing about an intermediate. A reduced dose might hold most of the effect, might hold very little, or might behave differently in someone who lost 30% of their body weight than in someone who lost 8%. All three are consistent with what has been published.

Prescribers do adjust doses downward in practice, and that is a clinical decision made with monitoring and a plan for what happens if weight starts moving. It is not the same as deciding on a taper alone.

Switching agents for maintenance

There is one piece of real maintenance evidence, and it is about switching rather than lowering.

A phase 3 trial found that people maintained their weight loss after switching from injectable incretin therapy to oral orforglipron, the first trial of its kind. The result is emerging rather than established, coming from a company announcement, and it should be read against the full publication when that appears.

Separately, oral semaglutide 25 mg was approved with an explicit long-term weight-maintenance indication alongside weight reduction, so maintenance is now something a label can say rather than only something clinicians improvise.

What a maintenance dose would have to preserve

Weight is the obvious endpoint and it is not the only one at stake.

The STEP 1 extension found the cardiometabolic improvements reversing alongside the weight regain, so a maintenance strategy is being asked to hold more than a number on a scale. And for anyone whose prescription was partly about cardiovascular risk, SELECT's 20% reduction in major adverse cardiovascular events was demonstrated at semaglutide 2.4 mg weekly over a median 39.8 months. A reduced maintenance dose has never been tested against that outcome, in either direction.

So the maintenance question splits in two. Whether a lower dose holds weight is unknown but researchable. Whether it holds cardiovascular benefit is unknown and nobody is currently running the trial that would answer it.

Why “off the drug” and “on a lower dose” are not the same experiment

This is the reasoning error to watch for on every maintenance page you read.

The argument usually runs: stopping causes regain, therefore staying on something is better than nothing, therefore a low dose works for maintenance. The first step is evidenced. The second is plausible. The third does not follow, because “better than nothing” and “as good as the label dose” are different bars, and only one of them has been measured against regain.

A page that quotes the STEP 1 extension and then recommends a maintenance microdose has performed that substitution in front of you.

What to discuss before tapering

Tapering after goal weight is a legitimate clinical conversation. It works better with an agreed plan and a tripwire.

• What would you consider a stable maintenance weight for me, and over what period?
• If we reduce the dose, how often would we weigh, and what change would trigger going back up?
• Am I on this drug for cardiovascular risk as well as weight, and does that change the plan?
• What is the evidence you are using for the dose you are proposing?
• If I regain, does going back up to the previous dose usually work?

The evidence, one row per claim

Sources

1. STEP 1 trial extension (PMC9542252)
2. Eli Lilly
3. Novo Nordisk
4. Secondary source characterising the evidence gap
5. American College of Cardiology, SELECT

Keep reading

• GLP-1 Microdosing: What the Term Means and What the Evidence ShowsThe term explained honestly: no regulator uses it, no trial tested it, and every dose-response curve in the fi
• Semaglutide Microdosing: The Ladder, the Data and the GapsThe label ladder laid next to the STEP programme, so you can see exactly how far a microdose sits from anythin
• Oral GLP-1 Options Compared: Orforglipron vs Oral Semaglutide 25 mgThe comparison people search for, with the honest caveat that nobody has run the trial that would settle it.
• Microdosing vs Standard Dosing: What the Trade-Off Actually IsThe four axes people are really weighing, and which of them have evidence at a low dose. Two do, one does not.